8 research outputs found

    E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease. Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown. We hypothesized that over-expressed transcription factors (TFs), as well as those that are driving the expression of the OEC over-expressed genes, could be the key for OEC genesis and potentially useful tissue and serum markers for malignancy associated with OEC.</p> <p>Methods</p> <p>Using a combination of computational (selection of candidate TF markers and malignancy prediction) and experimental approaches (tissue microarray and western blotting on patient samples) we identified and evaluated E2F5 transcription factor involved in cell proliferation, as a promising candidate regulatory target in early stage disease. Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.</p> <p>Results</p> <p>Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group than one covered by CA125, a conventional OEC biomarker. E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used). This significantly improved accuracy suggests possibility of an improved diagnostics of OEC. Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.</p> <p>Conclusions</p> <p>Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis.</p

    Revealing the pace of river landscape evolution during the Quaternary: recent developments in numerical dating methods

    Get PDF
    During the last twenty years, several technical developments have considerably intensified the use of numerical dating methods for the Quaternary. The study of fluvial archives has greatly benefited from these enhancements, opening new dating horizons for a range of archives at distinct time scales and thereby providing new insights into previously unanswered questions. In this contribution, we separately present the state of the art of five numerical dating methods that are frequently used in the fluvial context: radiocarbon, Luminescence, Electron Spin Resonance (ESR), 230Th/U and terrestrial cosmogenic nuclides (TCN) dating. We focus on the major recent developments for each technique that are most relevant for new dating applications in diverse fluvial environments and on explaining these for non-specialists. Therefore, essential information and precautions about sampling strategies in the field and/or laboratory procedures are provided. For each method, new and important implications for chronological reconstructions of Quaternary fluvial landscapes are discussed and, where necessary, exemplified by key case studies. A clear statement of the current technical limitations of these methods is included and forthcoming developments, which might possibly open new horizons for dating fluvial archives in the near future, are summarised

    Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

    No full text
    corecore